How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer Publisher Pubmed

Danbaran GR¹ ; Aslani S² ; Sharafkandi N³ ; Hemmatzadeh M⁴ ; Hosseinzadeh R² ; Azizi G⁵ ; Jadidiniaragh F^{6, 7} ; Babaie F⁸ ; Mohammadi H^{5, 9}

Show Affiliations

1. Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2. Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3. Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran
4. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
5. Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran
6. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
7. Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
8. Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran
9. Department of Immunology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran

Source: International Immunopharmacology Published:2020

Abstract

Programmed cell death-ligand 1 (PD-L1) is a glycoprotein that is expressed on the cell surface of both hematopoietic and nonhematopoietic cells. PD-L1 play a role in the immune tolerance and protect self-tissues from immune system attack. Dysfunction of this molecule has been highlighted in the pathogenesis of tumors, autoimmunity, and infectious disorders. MicroRNAs (miRNAs) are endogenous molecules that are classified as small non-coding RNA with approximately 20–22 nucleotides (nt) length. The function of miRNAs is based on complementary interactions with target mRNA via matching completely or incompletely. The result of this function is decay of the target mRNA or preventing mRNA translation. In the past decades, several miRNAs have been discovered which play an important role in the regulation of PD-L1 in various malignancies. In this review, we discuss the effect of miRNAs on PD-L1 expression and consider the effect of miRNAs on the synthetic pathway of PD-L1, especially during cancers. © 2020 Elsevier B.V.

Related Docs

View other Related Docs

1. Immune Checkpoints and Ncrnas: Pioneering Immunotherapy Approaches for Hematological Malignancies, Cancer Cell International (2024)

2. Exosomes and Micrornas in Biomedical Science, Synthesis Lectures on Biomedical Engineering (2022)

3. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)

4. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)

5. Micrornas Implications in the Onset, Diagnosis, and Prognosis of Osteosarcoma, Current Molecular Medicine (2021)

6. Regulation of Tumor Angiogenesis by Micrornas: State of the Art, Journal of Cellular Physiology (2019)

7. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)

8. Non-Coding Rnas As Potential Therapeutic Targets for Receptor Tyrosine Kinase Signaling in Solid Tumors: Current Status and Future Directions, Cancer Cell International (2024)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (17)

Fatemeh Atyabi (11)

Other Related Docs

9. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)

10. Recent Advances on High-Efficiency of Micrornas in Different Types of Lung Cancer: A Comprehensive Review, Cancer Cell International (2023)

11. Differential Role of Micrornas in Prognosis, Diagnosis, and Therapy of Ovarian Cancer, Biomedicine and Pharmacotherapy (2016)

12. Natural Killer Cell Epigenetic Reprogramming in Tumors and Potential for Cancer Immunotherapy, Epigenomics (2023)

13. Interferons: Role in Cancer Therapy, Immunotherapy (2020)

14. Coinhibition of S1pr1 and Gp130 by Sirna-Loaded Alginate-Conjugated Trimethyl Chitosan Nanoparticles Robustly Blocks Development of Cancer Cells, Journal of Cellular Physiology (2020)

15. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)

16. Cancer Genetics at a Glance: The Comprehensive Insights, Cancer Genetics and Psychotherapy (2017)

17. The Emerging Role of Lncrnas in Multiple Sclerosis, Journal of Neuroimmunology (2020)

18. Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity, IUBMB Life (2021)

19. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)

20. Inhibition of Hif-1Α/Ep4 Axis by Hyaluronate-Trimethyl Chitosan-Spion Nanoparticles Markedly Suppresses the Growth and Development of Cancer Cells, International Journal of Biological Macromolecules (2021)

21. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)

22. Efficacy of Nivolumab As Checkpoint Inhibitor Drug on Survival Rate of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: A Meta-Analysis of Prospective Clinical Study, Clinical and Translational Oncology (2019)

23. Immunopathology and Immunotherapy of Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)

24. Gynecologic Cancers and Non-Coding Rnas: Epigenetic Regulators With Emerging Roles, Critical Reviews in Oncology/Hematology (2021)

25. Codelivery of Stat3 Sirna and Bv6 by Carboxymethyl Dextran Trimethyl Chitosan Nanoparticles Suppresses Cancer Cell Progression, International Journal of Pharmaceutics (2020)

26. Epigenetics of Autoimmune Diseases, Prognostic Epigenetics (2019)

27. Targeting the Pd-1/Pd-L1 Pathway in Glioblastoma Multiforme: Preclinical Evidence and Clinical Interventions, International Immunopharmacology (2021)

28. Codelivery of Hif-1Α Sirna and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression, Pharmaceutical Research (2020)

29. Micrornas As Potential Diagnostic and Prognostic Biomarkers in Melanoma, European Journal of Cancer (2016)

30. Pdcd1 Single Nucleotide Polymorphisms in Iranian Patients With Juvenile Idiopathic Arthritis, Acta Medica Iranica (2017)

31. Nanomedicine for Improvement of Dendritic Cell-Based Cancer Immunotherapy, International Immunopharmacology (2020)

32. Anti-Inflammatory Micrornas and Their Potential for Inflammatory Diseases Treatment, Frontiers in Immunology (2018)

33. Recent Progress in Topical and Transdermal Approaches for Melanoma Treatment, Drug Delivery and Translational Research (2025)

34. Silencing of Hif-1Α/Cd73 Axis by Sirna-Loaded Tat-Chitosan-Spion Nanoparticles Robustly Blocks Cancer Cell Progression, European Journal of Pharmacology (2020)

35. Simultaneous Inhibition of Cd73 and Il-6 Molecules by Sirna-Loaded Nanoparticles Prevents the Growth and Spread of Cancer, Nanomedicine: Nanotechnology# Biology# and Medicine (2021)

36. Micrornas Targeting Programmed Cell Death Protein 1 (Pd-1) Promote Natural Killer Cell Exhaustion in Rheumatoid Arthritis, Iranian Journal of Allergy# Asthma and Immunology (2022)

37. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)

38. Inflammation Related Mirnas As an Important Player Between Obesity and Cancers, Journal of Diabetes and Metabolic Disorders (2019)

39. Blockade of Ctla-4 Increases Anti-Tumor Response Inducing Potential of Dendritic Cell Vaccine, Journal of Controlled Release (2020)

40. Combined Inhibition of Cd73 and Zeb1 by Arg-Gly-Asp (Rgd)-Targeted Nanoparticles Inhibits Tumor Growth, Colloids and Surfaces B: Biointerfaces (2021)

41. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)

42. Altered Mir-223 Expression in Sputum for Diagnosis of Non-Small Cell Lung Cancer, Avicenna Journal of Medical Biotechnology (2017)

43. Concomitant Blockade of A2ar and Ctla-4 by Sirna-Loaded Polyethylene Glycol-Chitosan-Alginate Nanoparticles Synergistically Enhances Antitumor T-Cell Responses, Journal of Cellular Physiology (2020)

44. The Role of Oncomirs in the Pathogenesis and Treatment of Breast Cancer, Biomedicine and Pharmacotherapy (2016)

45. The Role of Inflammation and Its Related Micrornas in Breast Cancer: A Narrative Review, Journal of Cellular Physiology (2019)

46. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)

47. Inhibition of Cd73 Using Folate Targeted Nanoparticles Carrying Anti-Cd73 Sirna Potentiates Anticancer Efficacy of Dinaciclib, Life Sciences (2020)

48. Targeting Regulatory T Cells by Curcumin: A Potential for Cancer Immunotherapy, Pharmacological Research (2019)

49. New Epigenetic Players in Stroke Pathogenesis: From Non-Coding Rnas to Exosomal Non-Coding Rnas, Biomedicine and Pharmacotherapy (2021)

50. Micrornas in Breast Cancer: Roles, Functions, and Mechanism of Actions, Journal of Cellular Physiology (2020)

Style	Citing Format
MLA	Danbaran GR, et al.. "How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer." International Immunopharmacology, vol. 84, no. , 2020, pp. -.
APA	Danbaran GR, Aslani S, Sharafkandi N, Hemmatzadeh M, Hosseinzadeh R, Azizi G, Jadidiniaragh F, Babaie F, Mohammadi H (2020). How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer. International Immunopharmacology, 84(), -.
Chicago	Danbaran GR, Aslani S, Sharafkandi N, Hemmatzadeh M, Hosseinzadeh R, Azizi G, Jadidiniaragh F, Babaie F, Mohammadi H. "How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer." International Immunopharmacology 84, no. (2020): -.
Harvard	Danbaran GR et al. (2020) 'How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer', International Immunopharmacology, 84(), pp. -.
Vancouver	Danbaran GR, Aslani S, Sharafkandi N, Hemmatzadeh M, Hosseinzadeh R, Azizi G, et al.. How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer. International Immunopharmacology. 2020;84():-.
BibTex	@article{ author = {Danbaran GR and Aslani S and Sharafkandi N and Hemmatzadeh M and Hosseinzadeh R and Azizi G and Jadidiniaragh F and Babaie F and Mohammadi H}, title = {How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer}, journal = {International Immunopharmacology}, volume = {84}, number = {}, pages = {-}, year = {2020} }
RIS	TY - JOUR AU - Danbaran GR AU - Aslani S AU - Sharafkandi N AU - Hemmatzadeh M AU - Hosseinzadeh R AU - Azizi G AU - Jadidiniaragh F AU - Babaie F AU - Mohammadi H TI - How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer JO - International Immunopharmacology VL - 84 IS - SP - EP - PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract